Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

SHAREHOLDER ALERT: Robbins LLP Investigates Generation Bio Co. (GBIO) on Behalf of Shareholders

December 29, 2021 GMT

SAN DIEGO--(BUSINESS WIRE)--Dec 28, 2021--

Shareholder rights law firm Robbins LLP is investigating Generation Bio Co. (NASDAQ: GBIO) to determine whether certain Generation Bio officers and directors violated the Securities Exchange Act of 1934 and breached fiduciary duties to shareholders. Generation Bio develops gene therapies for the treatment of rare and prevalent diseases.

If you would like more information about our investigation of Generation Bio Co.’s misconduct, click here.


Generation Bio Co. (GBIO) Reports Poor Results for Preclinical Studies for Hemophilia A Program

On December 14, 2021, Generation Bio issued a press release that “provided an update on factor VIII expression from a series of mouse and companion non-human primate (NHP) studies in hemophilia A, as well as an update on the development of its non-viral genetic medicine platform. Generation Bio’s proprietary genetic medicine technology comprises a closed-ended DNA (ceDNA) delivered via a novel, cell-targeted lipid nanoparticle (ctLNP).” The Company disclosed results that showed that in mice, ceDNA generated peak mean human factor VIII expression of 205% of normal at 2.0 mg/kg, and advised that “[a]dditional optimization is needed to translate the improvement in potency and reduction in variability observed in mice to [non-human primates], and to support nomination of a development candidate for the company’s hemophilia A program[.]” On this news, Generation’s stock price fell $7.91 per share to close at $5.99 per share on December 14, 2021.

Generation Bio Co. (GBIO) shareholders have legal options. If you own, or have previously owned, shares of Generation Bio Co., contact us for more information about your rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
Shareholder Information Form


About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Generation Bio Co. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on

CONTACT: Aaron Dumas

Robbins LLP

5040 Shoreham Place

San Diego, CA 92122

(800) 350-6003




Copyright Business Wire 2021.

PUB: 12/28/2021 07:37 PM/DISC: 12/28/2021 07:37 PM